Immunology and inflammation is the largest therapeutic area in biotechnology by revenue, anchored by the extraordinary commercial success of Dupixent (dupilumab) — Regeneron and Sanofi's IL-4/IL-13 dual blocker that generated over $14 billion in 2025 net sales across atopic dermatitis, asthma, COPD, eosinophilic esophagitis, and multiple other indications. The competitive landscape in immunology is intensely active — Amgen's bispecific antibody pipeline, new IL-33, TSLP, and OX40 inhibitor programs, and the emerging JAK inhibitor vs. biologic competition in inflammatory bowel disease and rheumatoid arthritis.
Topics Covered
• Immunology Biologic Market
• Dupixent Commercial Dominance
• IL-4
• IL-13 Pathway
• IL-33 and TSLP Pipeline
• IBD Biologic Landscape
• Rheumatology Biologics
• Amgen and Biogen Immunology Programs
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. Immunology Biologic Market
4. Dupixent Commercial Dominance
5. IL-4
6. IL-13 Pathway
7. IL-33 and TSLP Pipeline
8. IBD Biologic Landscape
9. Rheumatology Biologics
10. Amgen and Biogen Immunology Programs
11. Competitive Landscape
12. Competitive Landscape
13. Regional Market Analysis
14. Strategic Conclusions
15. Appendix
List of Tables
Table 1. Market Overview and Key Data 2025
Table 2. Immunology Biologic Market
Table 3. Dupixent Commercial Dominance
Table 4. IL-4
Table 5. IL-13 Pathway
Table 6. IL-33 and TSLP Pipeline
Table 7. IBD Biologic Landscape
Table 8. Rheumatology Biologics
Table 9. Amgen and Biogen Immunology Programs
Table 10. Competitive Landscape
Table 11. Leading Companies — Strategy Assessment 2025
Table 12. Pipeline Assessment 2025
Table 13. Key Risks and Mitigation Strategies
Companies Profiled
AbbVie
Roche
Johnson & Johnson
Sanofi
Regeneron
UCB
Bristol-Myers Squibb
Novartis
Pfizer
